Meeting Banner
Abstract #2536

Changes in White Matter Integrity in MS under Fingolimod Treatment for Two Years Revealed by HARDI

Jian Lin1, Pallab Bhattacharyya1, Ken Sakaie1, Robert Fox2, and Mark Lowe1

1Radiology, Cleveland Clinic, Cleveland, OH, United States, 2Neurology, Cleveland Clinic, Cleveland, OH, United States

In a 2 year longitudinal fingolimod study, we investigated the evolution of white matter integrity in the brain of relapsing-remitting multiple sclerosis (RRMS) patients under fingolimod treatment. Based on dMRI metrics from HARDI scans and statistical analysis, we found that MS patients experience a continued decline in white matter integrity during the first year of treatment with fingolimod with stabilization during the second year. Without a control group, it is unclear if these trends reflect on the impact of a treatment on disease progression.

This abstract and the presentation materials are available to members only; a login is required.

Join Here